Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2014-05-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration
NCT00691275
Comparing Speedlyte and IV Rehydration Treating Children With Gastroenteritis in a Pediatric Emergency Department (ED)
NCT03562702
A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis
NCT02699385
the Efficacy and Safety of Ondansetron Oral Soluble Pellicles
NCT06282211
Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?
NCT03262038
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
WHO ORS
Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
WHO ORS
Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
Commercial ORS
Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
Commercial ORS
Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WHO ORS
Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
Commercial ORS
Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Participants who lack the ability to provide informed consent
* Participants who are not anticipated to be on HPN for at least 6 months (determined by PrincipaI Investigator).
* Pregnant women
* Participants with pre-existing congestive heart failure, acute/ chronic kidney failure. (determined by the PrincipaI Investigator)
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ryan T. Hurt, M.D., Ph.D.
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ryan Hurt, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-008346
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.